Comparison of Movement Pattern Training and Manual Therapy for Prearthritic Hip Disorders

December 27, 2022 updated by: Washington University School of Medicine

Comparison of Movement Pattern Training and Manual Therapy for Prearthritic Hip Disorders: a Pilot Randomized Clinical Trial

Significance: Intra-articular, prearthritic hip disorders (PAHD) result in substantial dysfunction in young adults and are proposed precursors to hip osteoarthritis (OA). Our long term goal is to develop effective treatment strategies for people with PAHD that will improve function, decrease pain and prevent or delay the onset of OA. The purpose of this study is to compare movement pattern training (MoveTrain) and manual therapy (ManTher) in their effect on post-treatment, patient-reported outcomes and targeted impairments thought to contribute to PAHD.

This pilot study will collect sufficient data to power a future study that will determine the efficacy of MoveTrain compared to ManTher for people with PAHD. Participants with PAHD will be randomized into one of two treatment groups, MoveTrain or ManTher. The Hip disability and Osteoarthritis Outcome Score (HOOS) will be the primary outcome measure. A measure of hip adduction motion during functional tasks and quantitative sensory assessment (pain pressure threshold and temporal summation) will be the secondary measures used to assess the effect of respective treatment on the impairments thought to contribute to PAHD, thus addressing the mechanisms of pain. Upon completion of this study, we will be positioned to implement a large RCT (randomized clinical trial) to definitively assess the efficacy of MoveTrain and ManTher to improve PAHD.

Specific Aims: To obtain preliminary estimates of effect sizes for planning the future definitive randomized clinical trial,

Aim 1 (Function): we will compare post-treatment improvements in hip-specific, patient-reported outcomes among the two treatment groups. After treatment completion:

Aim 2 (Mechanism): we will compare pre- and post-treatment measures in lower extremity movement patterns during functional tasks (MoveTrain) and quantitative sensory testing (ManTher). After treatment completion:

Aim 3 (Prognosis): we will determine the association among personal factors at baseline (demographic and psychosocial) and treatment prognosis (improvement in HOOS).

Impact: Our line of research will improve our understanding of each proposed treatment and its effect on patient function and each treatment's targeted impairment. This improved understanding will lead to the development of treatment strategies that will ultimately result in comparative effectiveness studies of surgical and non-surgical treatment.

Study Overview

Study Type

Interventional

Enrollment (Actual)

33

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Missouri
      • Saint Louis, Missouri, United States, 63108
        • Program in Physical Therapy, Washington University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18-40 years

    • Must be scheduled before their 40th birthday
  • Have frequent hip joint symptoms, defined as pain, aching or stiffness within the hip joint for at least 3 months during the past 12 months
  • Hip joint pain confirmed upon physical exam
  • Report pain >= 3/10
  • Reports functional limitation as demonstrated by modified Harris Hip Score <90
  • Has protective sensation in the feet

Exclusion Criteria:

  • Previous hip surgery, fracture, pelvic/hip infection or cancer
  • Pain due to high impact trauma
  • Inflammatory disease, e.g. rheumatoid arthritis, gout
  • Acute pain in another joint that limits functional activities
  • Perthes disease or slipped capital femoral epiphysis
  • Hip pain referred from another source, e.g. lumbar spine
  • Neurological involvement affecting balance or coordination
  • Use of assistive gait device for more than 50% of time walking
  • Pain, numbness or tingling in the lower extremity
  • Pregnancy or given birth in previous 12 weeks
  • Unwilling to refrain from taking NSAIDs 1-2 days prior to testing session
  • Unable to attend regular physical therapy sessions
  • Unable to complete 12 month follow up session

    • Avascular Necrosis
    • Ehler's Danlos Syndrome

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Movement Pattern Training
Focus will be on task-specific training to improve lower extremity movement patterns during basic daily tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Tasks will be prioritized based on patient-report of activity limitations during the baseline examination. For example, during the first visit, the treating physical therapist will begin with the daily and patient-specific tasks that the patient reported as being most bothersome. Exercises will include repeated practice of functional tasks using optimized movement patterns. Based on the participant's performance, the difficulty of the task-specific activities will be progressed by varying the repetitions performed, increasing the load or changing the support surface. The home program will consist of repeated practice of tasks performed during the supervised sessions.
Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
Active Comparator: Manual Therapy (Joint Mobilization)
Focus will be on reducing pain and improving pain-free range of motion using manual techniques provided by the physical therapist and exercise performed in the home program. Patient education will include instruction to the benefits of manual therapy and the proposed effects on pain and joint mobility. Joint mobilizations to be used with each patient will be prioritized based on the restrictions, defined as stiffness or pain that is limiting joint range of motion, noted on the patient's baseline examination. For example, during the first visit, the treating physical therapist will begin with the two most restricted motions noted in the baseline exam and perform a standard assessment to determine treatment parameters. The home program will include joint range of motion and stretching exercises to complement techniques performed during the supervised sessions.
Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
Other Names:
  • Joint Mobilization

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Function Using the Hip disability and Osteoarthritis Outcome Score Activities of Daily Living Subscale
Time Frame: Immediately after treatment (13 weeks after baseline)
The Hip disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is score separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
Immediately after treatment (13 weeks after baseline)
Change in Function Using the Hip disability and Osteoarthritis Outcome Score Symptom Subscale
Time Frame: Immediately after treatment (13 weeks after baseline)
The Hip disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is score separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
Immediately after treatment (13 weeks after baseline)
Percentage of Participants Who Are Adherent to Treatment Attendance
Time Frame: Immediately after treatment (13 weeks after baseline)
Percentage of study participants who attend 90% (9/10) of the supervised treatment sessions.
Immediately after treatment (13 weeks after baseline)
Retention Rate
Time Frame: Immediately after treatment (13 weeks after baseline)
Percentage of those enrolled at baseline who completed testing after treatment
Immediately after treatment (13 weeks after baseline)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Home Exercise Program (HEP) adherence
Time Frame: Immediately after treatment (13 weeks after baseline)
Participants were instructed to perform their HEP 5 times per week1 time per day. The variable for HEP adherence was calculated as the total number of days reported by the participant to have completed the prescribed exercises, summed over the entire treatment period, and divided by the total number of treatment days.
Immediately after treatment (13 weeks after baseline)
Patient treatment receipt
Time Frame: Immediately after treatment (13 weeks after baseline)
The total number of exercises the physical therapist reviewed and the total number of those exercises they rated as independent were each summed across all treatment visits to derive the percent of exercises rated as independent across the entire treatment (Σ independent / Σ reviewed * 100).
Immediately after treatment (13 weeks after baseline)
Active ingredients for treatment delivery
Time Frame: Immediately after treatment (13 weeks after baseline)
Treatment delivery assessed using chart reviews to determine if the active ingredients of the treatment was provided. The variable for treatment delivery is the proportion of active ingredients completed and documented by the treatment physical therapists for XX treatment visits
Immediately after treatment (13 weeks after baseline)
Change in hip adduction angle
Time Frame: Immediately after treatment (13 weeks after baseline)
Change in hip adduction angle during functional tasks. Variable to assess movement pattern changes.
Immediately after treatment (13 weeks after baseline)
Change in hip adduction angle
Time Frame: On year after treatment completion
Change in hip adduction angle during functional tasks. Variable to assess movement pattern changes.
On year after treatment completion
Change in pain pressure threshold
Time Frame: Immediately after treatment (13 weeks after baseline)
Pain pressure threshold is assessed with an algometer. This is a quantitative sensory testing to assess the patient's sensitivity to stimuli.
Immediately after treatment (13 weeks after baseline)
Change in pain pressure threshold
Time Frame: One year after treatment completion
Pain pressure threshold is assessed with an algometer. This is a quantitative sensory testing to assess the patient's sensitivity to stimuli.
One year after treatment completion
Change in Function Using the Hip disability and Osteoarthritis Outcome Score Pain Subscale
Time Frame: Immediately after treatment (13 weeks after baseline)
The Hip disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is score separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
Immediately after treatment (13 weeks after baseline)
Change in Function Using the Hip disability and Osteoarthritis Outcome Score Pain Subscale
Time Frame: One year after treatment completion
The Hip disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is score separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
One year after treatment completion
Change in Function Using the Hip disability and Osteoarthritis Outcome Score Sport and Recreation Subscale
Time Frame: Immediately after treatment (13 weeks after baseline)
The Hip disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is score separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
Immediately after treatment (13 weeks after baseline)
Change in Function Using the Hip disability and Osteoarthritis Outcome Score Sport and Recreation Subscale
Time Frame: One year after treatment completion
The Hip disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is score separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
One year after treatment completion
Change in Function Using the Hip disability and Osteoarthritis Outcome Score Quality of Life Subscale
Time Frame: Immediately after treatment (13 weeks after baseline)
The Hip disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is score separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
Immediately after treatment (13 weeks after baseline)
Change in Function Using the Hip disability and Osteoarthritis Outcome Score Quality of Life Subscale
Time Frame: One year after treatment completion
The Hip disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is score separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
One year after treatment completion
Change in Function Using the Hip disability and Osteoarthritis Outcome Score Activities of Daily Living Subscale
Time Frame: One year after treatment completion
The Hip disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is score separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
One year after treatment completion
Change in Function Using the Hip disability and Osteoarthritis Outcome Score Symptom Subscale
Time Frame: One year after treatment completion
The Hip disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is score separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
One year after treatment completion
Change in movement evoked pain
Time Frame: Immediately after treatment (13 weeks after baseline)
Movement evoked pain was assessed as a Numeric Pain Rating Scale (NPRS) after performance of a repetitive step down task and a repetitive deep squat task.
Immediately after treatment (13 weeks after baseline)
Change in movement evoked pain
Time Frame: One year after treatment completion
Movement evoked pain was assessed as a Numeric Pain Rating Scale (NPRS) after performance of a repetitive step down task and a repetitive deep squat task.
One year after treatment completion
Change in Function Using the International Hip Outcome Tool (iHOT-33)
Time Frame: Immediately after treatment (13 weeks after baseline)
The iHOT is a hip-specific patient-reported outcome measure that represents the patient's report of symptoms, activity limitations, as well as emotional and social status. the score ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
Immediately after treatment (13 weeks after baseline)
Change in Function Using the International Hip Outcome Tool (iHOT-33)
Time Frame: One year after treatment completion
The iHOT is a hip-specific patient-reported outcome measure that represents the patient's report of symptoms, activity limitations, as well as emotional and social status. the score ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
One year after treatment completion
Change in Function Using the Patient Specific Functional Scale From Baseline to Post-treatment (13 Weeks)
Time Frame: Immediately after treatment (13 weeks after baseline)
The Patient Specific Functional Scale (PSFS), a patient-reported outcome measure of patient-specific activity limitations. Patients are asked to identify "3-5 activities you are unable to do or having difficulties performing due to the pain or symptoms in your hip". Patients then rated level of difficulty from 0-10, 0 indicating they are unable to perform the activity and 10 indicating they are able to perform the activity at their preinjury level. The final score is an average of all scores provided. Change was calculated by subtracting the baseline PSFS from the post-treatment PSFS.
Immediately after treatment (13 weeks after baseline)
Change in Function Using the Patient Specific Functional Scale From Baseline to Post-treatment
Time Frame: One year after treatment completion
The Patient Specific Functional Scale (PSFS), a patient-reported outcome measure of patient-specific activity limitations. Patients are asked to identify "3-5 activities you are unable to do or having difficulties performing due to the pain or symptoms in your hip". Patients then rated level of difficulty from 0-10, 0 indicating they are unable to perform the activity and 10 indicating they are able to perform the activity at their preinjury level. The final score is an average of all scores provided. Change was calculated by subtracting the baseline PSFS from the post-treatment PSFS.
One year after treatment completion
Change in Average Pain Intensity Quantified by a Numeric Pain Rating Scale (NPRS) From Baseline to Post-treatment
Time Frame: Immediately after treatment (13 weeks after baseline)
The numeric pain rating scale (NPRS) is a patient-reported outcome measure of pain intensity quantified using a 0-10 scale, 0 indicating the patient perceives no pain and 10 indicating the patient perceives the pain to be "worst pain imaginable". For average NPRS, patients are asked to rate what their pain was over the last week. Change was calculated by subtracting the baseline average NPRS from the post-treatment average NPRS.
Immediately after treatment (13 weeks after baseline)
Change in Average Pain Intensity Quantified by a Numeric Pain Rating Scale (NPRS) From Baseline to Post-treatment
Time Frame: One year after treatment completion
The numeric pain rating scale (NPRS) is a patient-reported outcome measure of pain intensity quantified using a 0-10 scale, 0 indicating the patient perceives no pain and 10 indicating the patient perceives the pain to be "worst pain imaginable". For average NPRS, patients are asked to rate what their pain was over the last week. Change was calculated by subtracting the baseline average NPRS from the post-treatment average NPRS.
One year after treatment completion
Change in Worst Pain Intensity Quantified by a Numeric Pain Rating Scale (NPRS) From Baseline to Post-treatment
Time Frame: Immediately after treatment (13 weeks after baseline)
The numeric pain rating scale (NPRS) is a patient-reported outcome measure of pain intensity quantified using a 0-10 scale, 0 indicating the patient perceives no pain and 10 indicating the patient perceives the pain to be "worst pain imaginable". For worst NPRS, patients are asked to rate what was their worst (highest) level of pain was over the last week. Change was calculated by subtracting the baseline worst NPRS from the post-treatment worst NPRS.
Immediately after treatment (13 weeks after baseline)
Change in Worst Pain Intensity Quantified by a Numeric Pain Rating Scale (NPRS) From Baseline to Post-treatment
Time Frame: One year after treatment completion
The numeric pain rating scale (NPRS) is a patient-reported outcome measure of pain intensity quantified using a 0-10 scale, 0 indicating the patient perceives no pain and 10 indicating the patient perceives the pain to be "worst pain imaginable". For worst NPRS, patients are asked to rate what was their worst (highest) level of pain was over the last week. Change was calculated by subtracting the baseline worst NPRS from the post-treatment worst NPRS.
One year after treatment completion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2019

Primary Completion (Anticipated)

December 31, 2022

Study Completion (Anticipated)

December 31, 2022

Study Registration Dates

First Submitted

May 20, 2019

First Submitted That Met QC Criteria

May 20, 2019

First Posted (Actual)

May 22, 2019

Study Record Updates

Last Update Posted (Actual)

December 28, 2022

Last Update Submitted That Met QC Criteria

December 27, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Femoroacetabular Impingement

Clinical Trials on Movement Pattern Training

3
Subscribe